This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ImmunoGen's TDM-1 Looks Strong at ESMO

Stocks in this article: IMGN

Updates with recent stock price.

BOSTON ( TheStreet) -- The "armed antibody" drug TDM-1 under development by Roche and ImmunoGen (IMGN) posted a higher response rate and lower toxicity than the blockbuster breast cancer drug Herceptin, according to results from the first head-to-head study of the two drugs to be presented at a European cancer meeting Monday.

The data from the TDM-1 phase II study in front-line breast cancer patients are early and very preliminary, but also encouraging because they suggest TDM-1 may be the next-generation successor to Herceptin that Roche has been looking for.

ImmunoGen, as Roche's partner on TDM-1, stands to profit as well if the drug is approved and successful.

In the phase II study, 137 women with HER2-positive metastatic breast cancer with no prior chemotherapy were randomly assigned to treatment with TDM-1 or Herceptin plus the chemotherapy drug Taxotere.

After six months of follow-up, the overall response rate for patients treated with TDM-1 was 48% compared to a 41% response rate for patients treated with Herceptin-Taxotere.

More striking was the difference in the rate of adverse events between the two drugs. The rate of "clinically relevant" adverse events (defined as Grade 3 or higher) was 37% in the TDM-1 arm compared to 75% in the Herceptin-Taxotere arm.

A full presentation of the T-DM1 study will be made Monday at the European Society of Medical Oncology (ESMO) annual meeting taking place in Milan.

Roche CEO Severin Schwan called the TDM-1 data "stunning" at a press event in Tokyo, according to a Reuters story Friday.

ImmunoGen shares were up 6% to $7.09 in late Friday trading.

T-DM1 is a so-called "armed antibody" that combines the targeted antibody drug Herceptin owned by Roche (already a potent cancer drug on its own) with a chemotherapy payload developed by ImmunoGen.

TDM-1 is designed to deliver a cancer-killing dose of chemotherapy directly inside tumors, sparring healthy cells from toxic side effects. This may explain the sharply lower toxicities observed in the front-line breast cancer study of TDM-1 compared to Herceptin-Taxotere.

For instance, the rates of hair loss and neutropenia (low white blood cell counts) in the Herceptin-Taxotere arm were 66% and 57%, respectively. By comparison, hair loss and neutropenia were reported in 1.5% and 7.5% of TDM-1 patients, respectively.

More patients treated with TDM-1 reported fever and nausea than those treated with Herceptin-Taxotere.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs